Best Skin Firming Face Cream - What You Can Do For Skin Firming Before Its Too Late

Best skin firming face creams and treatments gain paramount importance as we mature towards the thirties and forties. Here is your inside guide on what works and what does not when it comes to your skin firming efforts.

When we were young we had smooth, firm and supple skin. But then as a more mature age of the thirties and forties began to dawn upon us, skin aging symptoms such as wrinkles, saggy skin and uneven skin complexion begin to show up.

But thankfully, due to major advancements in modern medical science, best skin firming face creams have been pioneered which make skin rejuvenation very easy. Not only do the results come very quickly, but the skin firming also lasts for a very long period and improves over time!

The key lies in the two vital proteins - collagen and elastin. They are responsible for keeping our skin firm, supple, pliant and elastic. They are sufficiently produced while we are young, but their natural output slows down as we age. And the key to re-start the fountain of youth within our body is to enhance the natural production of collagen and elastin by the body itself.

One of the amazing cutting edge natural ingredients. It has been pioneered in New Zealand and is being successfully used in the best face cream with snow algae. It has effectively proven itself in clinical trials on human volunteers to improve natural production of collagen and elastin in the body.

The proteins have a significant and long term effect on skin firming, by increasing its elasticity and moisture retention. Studies showed a sustained 14% improvement in skin moisture retention and 42% improvement in elasticity over 18 days.

These are fairly amazing results especially when they have been achieved in such a short span of time. As if this wasn't enough, is also a powerful and highly effective antioxidant. Its unique enzymatic form of antioxidants neutralizes free radicals before they are able to damage the skin cells and tissues.

Related Post: Why You Want Snow Algae In Your Face Cream 

Hospedaje Web

Un servicio de hospedaje web es un tipo de servicio de hospedaje de Internet que permite a las personas y organizaciones interesadas hacer que su sitio web sea accesible a través de la World Wide Web. También es un servicio que hace que su sitio web esté disponible para ser visto por otros en Internet. Un host web proporciona espacio en su servidor, para que otras computadoras de todo el mundo puedan acceder a su sitio web a través de una red o un módem. Es imprescindible conocer los beneficios del hospedaje web para permitir que los hombres de negocios brinden a sus clientes la calidad adecuada de los servicios.

Beneficios del servicio de hospedaje web

1. Reduce los costos: esto se debe a que la empresa de hospedaje web en méxico generalmente emplea a personas que se encargarán de cualquier problema relacionado con su sitio web. Lo que hay que hacer es pagar los servicios de acuerdo con el acuerdo entre él y la empresa que aloja su sitio web.

2. Es bueno para la optimización: en la actualidad, muchos posibles compradores poseen un teléfono inteligente, una tableta o un navegador. El mejor sitio web requiere proporcionar a todos los posibles visitantes un recorrido suave de su elección de gadget. Los servicios de hospedaje web experto a menudo cubren este tipo de optimización integrable.

3. Ayuda a entregar ideas, productos y servicios a todo el mundo utilizando una red web bien diseñada.

4. Le permite crear la base de datos que es simplemente indispensable para los propietarios de negocios en línea.

5. Ofrece copias de seguridad vitales: si su servidor falla, es un desastre evidente. Pero cuando se aloja no pierde todo, ya que estos servicios incluyen copias de seguridad de rutina. Estas copias de seguridad de rutina garantizan que recupere todo lo que había trabajado. Por lo tanto, es más confiable que tener un sistema personal.

6. Ofrece un servicio que le proporciona una cuenta de correo electrónico. Esto se atribuye al hecho de que es una forma ideal de establecer su profesionalismo y también aumenta el nivel de confiabilidad del cliente.

7. Mantiene los enlaces marcados. Los enlaces muertos muchas veces le niegan al sitio web el jugo que se merece. Además, genera altas tasas de rebote y conversiones mínimas. Al final de esto, se pierde. Pero con el host web, esto a menudo se minimiza. Esto se debe a que parte del trabajo del anfitrión es vigilar los enlaces y actualizarlos cada vez que mueren. Esto mantiene el sitio web muy activo.

Related Post: Obtenga un plan de hospedaje web asequible

How to Dose Andarine S4 Properly

When balancing your Andarine dose, it is a good idea to talk to your doctor first to decide if it is the right step for you. Most doctors should have a pretty good understanding of the effects of this supplement and can give you an insight into what to expect from it. If your family doctor doesn’t know about it, talk to a dietitian that does. They will perform tests to make sure your body is prepared for it.

Typically, most people take Andarine at a pretty reasonable level. It usually starts out at about 50 milligrams and can expand to 75 milligrams. These doses should be taken five days a week to avoid complications. During these days, you should exercise for 30-60 minutes to get the maximum effect of Andarine. Your dose can be split up into three different times, such as during your three meals of the day, or taken all at once.

You should never take Andarine for more than 12-16 weeks or go past your 75-milligram dosage. While the athlete above increased their dosage as high as 125 milligrams, he only increased the side effects and not the positive benefits. That’s because Andarine has what is known as a point of diminishing returns. As a result, increasing your dosage past 75 milligrams or your usage period longer than 16 weeks won’t offer you any benefits.

In fact, it is possible that you will suffer from what is known as AR desensitization. While not a permanent problem, it will negate the positive side effects of Andarine. As a result, it is possible that you could lose muscle mass while your body is normalizing. So keep your dose at below 75 milligrams to avoid this concern.

The two-day break should be back-to-back as a way of helping avoid serious side effects. It is a good idea to work out during the weekdays with Andarine and then take a break during the weekend. That doesn’t mean you can’t workout on Saturday and Sunday. It just means you don’t take Andarine while you do it. Failure to take a two-day break will cause some vision problems to be discussed below.

Related Post: What is S4 Andarine?

What Is Drug Rivaroxaban powder(Xarelto) Use For

Content

1. What is Rivaroxaban powder? Rivaroxaban reviews .................................................................... 1

What is Rivaroxaban powder: ................................................................................................... 1

Rivaroxaban powder usage: ...................................................................................................... 2

Rivaroxaban metabolism: .......................................................................................................... 2

2. Rivaroxaban mechanism of action ................................................................................................ 3

3. Rivaroxaban half life...................................................................................................................... 3

4. What is the drug Rivaroxaban used for?....................................................................................... 3

5. Rivaroxaban dosage ...................................................................................................................... 3

How to use Rivaroxaban? .......................................................................................................... 3

Rivaroxaban(Xarelto)   Overdose .............................................................................................. 4

Rivaroxaban(Xarelto)   Missed Dose ......................................................................................... 5

6. Can you drink alcohol while taking Rivaroxaban?......................................................................... 5

7. What medications should not be taken with Xarelto(Rivaroxaban powder)?..............................6

8. How long does it take for Rivaroxaban to get out of your body? ................................................. 6

9. What foods to avoid while on Xarelto(Rivaroxaban powder)....................................................... 7

10. Can I just stop taking Rivaroxaban? ............................................................................................ 7

11. What are the side effects of Rivaroxaban? ................................................................................. 8

12. What is the cost of Rivaroxaban(rivaroxaban cost)? .................................................................. 9

13. Buy Rivaroxaban powder from AASraw with the best price ....................................................... 9

1. What is Rivaroxaban powder? Rivaroxaban reviews

What  is  Rivaroxaban  powder:

Rivaroxaban powder/Xarelto powder, brand name is Xarelto, and others. It is a morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Rivaroxaban powder/Xarelto powder is an anticoagulant which binds directly to factor Xa. Thereafter, it effectively blocks the amplification of the coagulation cascade, preventing the formation of thrombus. Rivaroxaban is a unqiue anticoagulant for two reasons. First of all, it is does not involve antithrombin III (ATIII) to exert its anticoagulant effects. Secondly, it is an oral agent whereas the widely used unfractionated heparin and low molecular weight heparins are for parenteral use only. Although the activated partial thromboplastin time (aPTT) and HepTest (a test developed to assay low molecular weight heparins) are prolonged in a dose-dependant manner, neither test is recommended for the assessment of the pharmacodynamic effects of rivaroxaban. Anti-Xa activity and inhibition of anti-Xa activity monitoring

is also not recommended despite being influenced by rivaroxaban.

Rivaroxaban  powder  usage:

Following oral administration, rivaroxaban powder is rapidly absorbed and reaches peak plasma concentration in 2-4 hours. Bioavailability of the 10 mg dose is >80%. However, the 15-20 mg dose have a lower bioavailability if taken in the fasted state and consequently should be taken with food.

Rivaroxaban metabolism:

Approximately two-thirds of rivaroxaban is excreted into urine (via active tubular secretion in which approximately 36% as unchanged drug and 30% as inactive metabolism). The remaining third of the administered dose is excreted via feces in which 7% is in the form of unchanged drug and 21% as inactive metabolites.

2. Rivaroxaban mechanism of action

Rivaroxaban (Xarelto) is an oral anticoagulant (blood thinner) that is used to prevent and treat blood clots. Blood clots formed in the heart are dangerous since they can travel to the brain and cause a stroke. Similarly, blood clots formed in the legs or

lungs can be equally life threatening if not treated. Rivaroxaban(Xarelto) is a selective inhibitor of factor Xa, an enzyme necessary to form blood clots. It reduces the ability of blood to clot. The FDA approved Xarelto in July, 2011.

3. Rivaroxaban half life

The terminal rivaroxaban half life is 5-9 hours in adults and 11-13 hours in the elderly.

4. What is the drug Rivaroxaban used for?

-reduce the risk of stroke and blood clots in patients with atrial fibrillation not due to a heart valve problem,

-treat and reduce the risk of deep vein thrombosis (DVT, blood clots in the veins of the legs) and pulmonary embolism (PE, blood clots in the lungs)

-reduce the risk of blood clots in the legs and lungs of patients who have just had hip or knee replacement surgery.

5. Rivaroxaban dosage

How to  use  Rivaroxaban?

Rivaroxaban(Xarelto) is available in 10, 15, and 20 milligram (mg)

tablets(rivaroxaban 20mg)that you take by mouth.

For treating DVT or PE, the typical dose is 15 mg twice daily with food for the first 21 days. After that, people usually take 20 mg(rivaroxaban 20mg) once a day for the remainder of their treatment.

For nonvalvular atrial fibrillation, the typical starting rivaroxaban dose is either 15 or 20 mg (ravaroxaban dosing)once in the evening, with a meal.

To prevent DVT or PE, people usually take 10 mg of rivaroxaban dose once a day, with or without food.

After hip or knee replacement surgery, the usual recommendation is to start treatment at least 6 to 10 hours after surgery. People who've had a hip replacement generally are prescribed 10 mg of the rivaroxaban dosage for 35 days.

If you've had a knee replacement procedure, you can take rivaroxaban dosing for 12 days following surgery.

Be sure to take Rivaroxaban(Xarelto) to at about the same time each day.

If you have difficulty swallowing the tablets, you can crush them and mix them with applesauce. Eat the mixture right away, followed by additional food.

Rivaroxaban(Xarelto)  Overdose

If you take too much Rivaroxaban(Xarelto) , you could bleed internally, or hemorrhage.

Symptoms of an overdose may include: Abnormal bleeding or bruising

Bloody or black stools

Blood in urine

Coughing up blood or vomiting blood

If you or someone else has symptoms of an overdose, call your doctor right away or go to the nearest emergency room. If someone taking Xarelto collapses or isn't breathing, call 911.

Rivaroxaban(Xarelto)  Missed  Dose

Be sure to take the drug as prescribed by your doctor, even if you feel well. Don't stop taking Rivaroxaban(Xarelto)   without talking to your doctor first because you're at greater risk of stroke after you stop taking this medication.

If you're supposed to take Rivaroxaban(Xarelto)  once a day but miss a dose, take the missed dose as soon as you remember that day. Go back to your normal treatment schedule the next day.

If you take Rivaroxaban(Xarelto)  twice a day, take the missed dose as soon as you remember it on the same day. You can take even two doses of the medication at the same time to make up for the missed dose.

The next day, stick to your usual dosing schedule.

6. Can you drink alcohol while taking Rivaroxaban?

Daily use of alcohol while using Rivaroxaban will increase your risk for stomach bleeding. Limit alcoholic beverages. Ask your doctor or pharmacist about how much alcohol you may safely drink. Rivaroxaban can cause bleeding.

6.  What medications should not  be  taken  with Xarelto(Rivaroxa ban powder)?

Rivaroxaban contraindications, what medications should not be taken with Xarelto(Rivaroxaban anticoagulant)?

The CYP3A4 liver enzymes and P-glycoprotein (P-gp) drug transporter systems are primarily responsible for metabolizing and removing Rivaroxaban to from the body. Taking Xarelto with medicines that alter the activity of both the CYP3A4 enzymes and P-gp drug transporters may affect blood levels of Rivaroxaban. Rivaroxaban should not be taken with:

-ketoconazole (Nizoral),

-ritonavir (Norvir),

-clarithromycin (Biaxin),

-erythromycin (Ery-Tabs),

-fluconazole (Diflucan),

-carbamazepine (Tegretol),

-phenytoin (Dilantin),

-rifampin (Rimactane), or,

-St. John's Wort.

Rivaroxaban anticoagulant to should not be used with other blood thinners due to the increased risk of bleeding.

8. How long does it  take for Rivaroxaban to get out of your bo dy?

As warfarin's blood thinning effect sticks around for several days after it has been stopped, discontinuation 5- 7 days before surgeries is typically needed. Rivaroxaban, on the other hand, is relatively quickly out of the system. Discontinuation 24 to 36 hours before surgeries is typically enough.

9. What foods to avoid while on Xarelto(Rivaroxaban powder)

Rivaroxaban has no known dietary restrictions. Rivaroxaban doesn't interact with vitamin K like warfarin does. So you can enjoy healthy options like leafy green vegetables and other foods rich in vitamin K whenever you like, without having to worry about them changing the way Rivaroxaban works.

10. Can I just stop taking Rivaroxaban?

You are at risk of stroke from AFib even if you don't feel symptoms. Don't stop taking Rivaroxaban(Xarelto) unless your doctor tells you to. Stopping Rivaroxaban(Xarelto) increases your risk of having a stroke. If you have to stop taking

Rivaroxaban(Xarelto), your doctor may prescribe another blood thinner to help prevent blood clots from forming.

11. What are the side effects of Rivaroxaban?

Along with its needed effects, a medicine may cause some unwanted Rivaroxaban side effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following Rivaroxaban side effects occur:

More common

-Back pain

-bleeding gums

-bloody stools

-bowel or bladder dysfunction

-burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings

-coughing up blood

-difficulty with breathing or swallowing

-dizziness

-headache

-increased menstrual flow or vaginal bleeding

-leg weakness

-nosebleeds

-numbness

-paralysis

-prolonged bleeding from cuts

-red or black, tarry stools

-red or dark brown urine

-vomiting of blood or material that looks like coffee grounds

Less common

-Fainting

-pain in the arms or legs

-wound secretion

12. What is the cost of Rivaroxaban(rivaroxaban cost)?

At a monthly cost of approximately $255 for a 20-mg daily dosage, rivaroxaban cost is significantly more expensive than warfarin (approximately $6 for a 30-day supply of 1-, 2-, 2.5-, or 5-mg tablets; and between $6 and $7 for a 30-day supply of 7.5- or

10-mg tablets), and roughly the same price as dabigatran (approximately $255 for a one-month supply of 150 mg twice daily).

13. Buy Rivaroxaban powder from AASraw with the best price

Rivaroxaban is a new and leading drug, the rivaroxaban cost of course expensive than normal products. AASraw is a professional manufacturer that provide high quality

raw powder, include steroids raw powder, sex hormone material, fat loss material...etc. AASraw have professional lab and cooperate with famous university lab, famous hospital, can guarantee high quality. And can provide bulk order with factory price. Buy Rivaroxaban powder from AASraw with the best price.

Related Post: What Is Drug Rivaroxaban powder(Xarelto) Use For

Crizotinib powder 877399-52-5 is an anti-cancer agent acting

1.What is Crizotinib?

Crizotinib(trade name Xalkori, Pfizer) is an anti-cancer drug acting as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor, approved for treatment of some non-small cell lung carcinoma (NSCLC) in the US and some other countries, and undergoing clinical trials testing its safety and efficacy in anaplastic large cell lymphoma, neuroblastoma, and other advanced solid tumors in both adults and children.

Crizotinib is an anti-cancer agent acting as anaplastic lymphoma kinase inhibitor and recently approved for treatment of non-small cell lung carcinoma.The retrosynthetic analysis of this molecule clearly takes our eyes to two major building blocks, as described in Scheme 1, being the racemic 1-(2,6-dichloro-3-fluorophenyl)ethanol a very interesting target for biotransformations. Indeed, some research groups have already reported their results on biocatalytic or biotransformation approaches for arriving on the desired intermediate.

2.How does Crizotinib works?

Crizotinib has an aminopyridine structure, and functions as a protein kinase inhibitor by competitive binding within the ATP-binding pocket of target kinases. About 4% of patients with non-small cell lung carcinoma have a chromosomal rearrangement that generates a fusion gene between EML4 ('echinoderm microtubule-associated protein-like 4') and ALK ('anaplastic lymphoma kinase'), which results in constitutive kinase activity that

contributes to carcinogenesis and seems to drive the malignant phenotype.The kinase activity of the fusion protein is inhibited by crizotinib. Patients with this gene fusion are typically younger non-smokers who do not have mutations in either the epidermal growth factor receptor gene (EGFR) or in the K-Ras gene. The number of new cases of

ALK-fusion NSLC is about 9,000 per year in the U.S. and about 45,000 worldwide.

ALK mutations are thought to be important in driving the malignant phenotype in about

15% of cases of neuroblastoma, a rare form of peripheral nervous system cancer that occurs almost exclusively in very young children.

Crizotinib inhibits the c-Met/Hepatocyte growth factor receptor (HGFR) tyrosine kinase, which is involved in the oncogenesis of a number of other histological forms of malignant neoplasms.

Crizotinib is currently thought to exert its effects through modulation of the growth, migration, and invasion of malignant cells. Other studies suggest that crizotinib might also act via inhibition of angiogenesis in malignant tumors.

In order to get chiral 1-phenylethanol derivative, Liang and co-workers have used several microorganism for efficient reduction the ketone towards intermediate. Other groups tried to increase the efficiency and selectivity towards the chiral intermediate by using similar approaches. A fit-for-purpose route published by Koning and co-workers from Pfizer revels the strategy for producing the racemic alcohol by traditional NaBH4 reduction, followed by acetylation, resolution mediated by PLE and Mitsunobu inversion towards the required enantiomer.

Lipases are always the first option when thinking about obtaining highly enantiomeric pure chiral alcohols by kinetic resolutions or dynamic kinetic resolution (DKR) methods. Furthermore, lipases can be combined with racemization catalysts, namely palladium, iridium, vanadium or ruthenium complexes complexes. Unfortunately, to the best of our knowledge, no reports of lipases used on the kinetic or DKR of

1-(2,6-dichloro-3-fluorophenyl)ethanol were found.

In our continuous effort towards the development of biocatalytic protocols for the synthesis of intermediates for API synthesis, herein, we report our studies on the kinetic and DKR of 1-(2,6-dichloro-3-fluorophenyl)ethanol, an important intermediate on Crizotinib synthesis.

3.Crizotinib Materials and methods

Name:     Crizotinib powder

CAS:    877399-52-5

Molecular Formula:    C21H22Cl2FN5O

 

Molecular Weight:    450.343

Melt Point:    197-203°C Storage Temp:    RT

Color:    white to pale-yellow powder

1-(2,6-Dichloro-3-fluoro-phenyl)-ethanol and isopropenyl acetate purchased from

Sigma-Aldrich. Candida antarctica lipase B (CAL B) purchased from Novozymes. All other materials were at least reagent-grade.

·     Kinetic resolution reactions

The reaction mixture was composed by a 3 mL solution of 0.048 mmol

1-(2,6-dichloro-3-fluoro-phenyl)-ethanol, 0.096 mmol acyl donor and 60 mg of enzyme (20% w/v) in solvent. The screening reactions were performed in silicon carbide plates at temperatures of 60–80 °C, under magnetic stirring to obtain

1-(2,6-dichloro-3-fluorophenyl)ethyl acetate (1H NMR (300 MHz, CDCl3) δ 7.26 (dd, J =

8.3, 5.6 Hz, 5H), 7.03 (t, J = 8.5 Hz, 3H), 6.39 (q, J = 7.1 Hz, 3H), 2.09 (s, 3H), 1.66 (d, J =

6.9 Hz, 3H). In order to screen the influence of the different reaction medium’s components, enzymes, solvent, acyl donor and temperature were evaluated. A 20 μL aliquot was transferred to a new vial and 980 μL of ethyl acetate was added and analyzed in the GC-FID.

·     Dynamic kinetic resolution (DKR) reactions in continuous flow

Continuous flow experiments were performed using an Asia Flow System (Syrris) which included a syringe pump, a heater and a glass column. The glass column was packed with immobilized CAL B and VOSO4.XH2O alternately. A 10 mL-packed-bed reactor with 4 layers of enzyme (each layer containing 500 mg of the catalyst) and 3 layers of VOSO4.XH2O (each layer containing 500 mg of the catalyst) separated by thin cotton layers was obtained. The bed-packed reactor was heated at 80 °C and perfused with isooctane at a flow rate of 1.0 mL.min?1. Continuous flow reactions were carried out by pumping a isooctane solution (15 mL) of 1-(2,6-dichloro-3-fluoro-phenyl)-ethanol (0.1 M) and vinyl acetate as acyl donor (0.1 M) through the bed-packed reactor at flow rates of 0.1,

0.5 and 1.0 mL.min?1, which correspond to residence times of 100, 50 and 10 min, respectively. Due to the long reaction time in batch, the solution was recycled in the continuous flow to optimize the conversion results. Aliquots of 20 μL were collected from the output of the reactor after pumping the reactional solution for two times the residence time and after 21 h. Afterwards, the aliquots were diluted with ethyl acetate to 1.0 mL solution and analyzed by GC-FID.

·     Chromatography analysis

Kinetic Resolution and Dynamic Kinetic Resolution

1-(2,6-Dichloro-3-fluorophenyl)-ethanol GC-FID: (Shimadzu CG2010 – chiral capillary column Gamadex – 225) 8 μL samples were injected at 117 °C. The oven was heated at

2 °C/min to 150 °C then maintained for 5 min and at 30 °C/min to 200 °C and then maintained for 1 min, with a 3.0 mL/min flow, and a Split injection mode (Ratio: 20:1).

·     Results and discussions

Based on our previous experience on kinetic resolutions of sec-phenylethanol derivatives, we have learned along these years that ortho-substituted aryl alcohols are less reactive for the kinetic resolution. Since 1-(2,6-dichloro-3-fluorophenyl)ethanol (2) contains substituents on both ortho positions, we were expecting long reaction times for this transformation. We have started by screening the influence of acyl donor on the reaction outcome when using commercial immobilized CAL B (N435) at 60 °C and cyclohexane as solvent for 10 days (Table 1).

Acyl donor evaluation for kinetic resolution of 1-(2,6-dichloro-3-fluorophenyl)ethanol (2)

mediated by immobilized CAL-B.

Entry    Acyl Donor (1 eq)    Conv. (%)    e.e.prod (%)    E

1    Isopropenyl acetate    44    99    >200

2    Ethyl acetate    32    99    >200

3    Vinyl acetate    26    95    54

Reaction conditions: 1-(2,6-dichloro-3-fluorophenyl)-ethanol (2) (0.048 mmol, 10mg), isopropenyl acetate or vinyl acetate or ethyl acetate (1eqv) as acyl donor, and 60mg (20%w/v) of CAL B Novozym 435 (N435) in cyclohexane (3 mL) for 10 days at 60 °C, measured by GC-FID method and enantioselectivity was measured based on

(S) -1-(2,6-dichloro-3-fluorophenyl)ethanol and the corresponding ester retention times.

4. Approvals and indications for Crizotinib

On August 26, 2011, the U.S. Food and Drug Administration approved crizotinib (Xalkori) to treat certain late-stage (locally advanced or metastatic) non-small cell lung cancers that express the abnormal anaplastic lymphoma kinase (ALK) gene. Approval required a companion molecular test for the EML4-ALK fusion. In March 2016, the U.S. Food and Drug Administration approved crizotinib in ROS1-positive non-small cell lung cancer.

As expected, isopropenyl acetate lead to the best results on the kinetic resolution of

1-(2,6-dichloro-3-fluorophenyl)ethanol (2), arriving on the desired acetylated

R-enantiomer in good conversions and high selectivity (Table 1, entry 1). Vinyl acetate was probably too reactive under the designed reaction conditions, leading to a decrease of enantiomeric ratio. A blank experiment was performed in order to evaluate the uncatalyzed reaction and small amounts of acetylated alcohol could be obtained (<10%). Regarding ethyl acetate, surprisingly, it presented interesting selectivity with moderate conversion (Table 1, entries 3 and 2 respectively). Despite the fact that Table 1 present

the results for the kinetic resolution after 10 days, the reactions were monitored in the first

3 days every 12 h and after the 3rd day, every 24 h. What could be seen is the conversion improvement along the days until 10 days of reaction. Further reaction time has also been evaluated (12 days) but no improvement on conversion was observed.

In order to try to reduce the reaction time, one of the strategies was to evaluate the effect of higher proportions of acyl donor but unfortunately with values higher then two equivalents the enantiomeric ratio dropped from >200 to 31, showing that the chemical esterification is taking place. Another attempt was to screen other lipases but no better results were found when compared to the commercial immobilized CAL B (N435) (Table S1 – Supporting information).

In order to try to reduce the long reaction time obtained for this specific substrate, different temperatures and solvents were evaluated.

Solvent screening for kinetic resolution of 1-(2,6-dichloro-3-fluorophenyl)ethanol, using isopropenyl acetate mediated by immobilized CAL B.

Entry    T (°C)    Solvent    Time (Days)    Conv. (%)    e.e.prod (%)    E

1    60    ACN    5    2    99    >200

2    60    Acetone    5    n.d.    n.d.    n.d.

3    60    MTBE    5    n.d.    n.d.    n.d.

4    60    Toluene    5    11    99    >200

5    60    Hexane    6    n.d.    n.d.    n.d.

6    60    Heptane    6    44    99    >200

7    60    Isooctane    6    39    99    >200

8    70    Isooctane    5    45    99    >200

9    75    Isooctane    5    40    99    >200

10    80    Isooctane    5    44    99    >200

Reaction conditions: 1-(2,6-dichloro-3-fluorophenyl)ethanol (2) (0.048 mmol, 10mg), isopropenyl acetate (2eqv) as acyl donor, and 60mg (20%w/w) Novozym 435 in different solvents (3 mL, ACN – acetonitrile, MTBE – methyl ter-butyl ether), measured by GC-FID method and enantioselectivity was measured based on

(S)-1-(2,6-dichloro-3-fluorophenyl)ethanol and the corresponding ester retention times.

As observed on Table 2, among all solvents evaluated for the desired resolution, isooctane presented the best results in terms of reaction time. Under the conditions studied, at 70 °C, isooctane could lead to 45% of conversion (42% yield) after 5 days, a

50% reduction on reaction time (Table 2, entry 7). Other solvents as acetone, MTBE,

acetonitrile (ACN), toluene and hexane, have failed or lead to very poor conversions. At higher temperatures, no improvement on reaction conversion could be observed. An exception is heptane, which could lead to similar results to isooctane, but the later can lead us to a better stability for the immobilized enzyme.

Despite the good results obtained under kinetic resolution conditions, 50% of the product is waste or need to be racemized in order to be used again in another campaign.

Based on the results obtained for the kinetic resolution of

1-(2,6-dichloro-3-fluorophenyl)ethanol (2), we decided to move forward in order to develop a method for the DKR which should deliver the desired acetylated R-enantiomer of 1-(2,6-dichloro-3-fluorophenyl)ethanol (2) as main product. This strategy is based on the fact that after DKR, a simple hydrolysis leads to the desired enantiomer, which can be coupled with the side chain through standard nucleophilic aromatic substitution procedure. Two different racemization catalysts were tested for this purpose, vanadyl sulfate19–25 and Shvo’s ruthenium catalyst.26–30.

The reactions were carried out at 70 °C, using isopropenyl acetate as acyl donor and the conversion analyzed by GC-FID daily during 5 days. It is important to note that short chain acyl donors are not the best choice for DKR mediated by vanadium catalysts, as already reported by other groups.20,22 Despite that, we decided to keep isopropenyl acetate since we already know that the kinetic resolution should be the rate limiting step of our process and a long chain acyl donor, as vinyl decanoate, could increase even more the reaction time.31 The results obtained for the dynamic kinetic resolution are presented on Table 3.

DKR of 1-(2,6-dichloro-3-fluorophenyl)ethanol (2) mediated by immobilized CAL-B and different racemization catalysts under batch conditions.

Entry    Racemization Catalyst    Conv. (%)    e.e.prod (%)    Selectivity (%)

1    VOSO4    30    98    >99

2    Shvo    35    92    >99

Reaction conditions:1-(2,6-dichloro-3-fluoro-phenyl)-ethanol (0,1 M), isopropenyl acetate (0,1 M) as acyl donor, in isooctane (15 mL) were carried by mixing all reagents and catalysts on a batch reactor. Determined by GC-FID and enantioselectivity was measured based on (S)-1-(2,6-dichloro-3-fluorophenyl)ethanol and the corresponding ester retention times.

5.Clinical trials for Crizotinib

Crizotinib caused tumors to shrink or stabilize in 90% of 82 patients carrying the ALK fusion gene. Tumors shrank at least 30% in 57% of people treated. Most had adenocarcinoma, and had never smoked or were former smokers. They had undergone treatment with an average of three other drugs prior to receiving crizotinib, and only 10% were expected to respond to standard therapy. They were given 250 mg crizotinib twice daily for a median duration of six months. Approximately 50% of these patients suffered at least one side effect, such as nausea, vomiting, or diarrhea. Some responses to crizotinib have lasted up to 15 months.

A phase 3 trial, PROFILE 1007, compares crizotinib to standard second line chemotherapy (pemetrexed or taxotere) in the treatment of ALK-positive NSCLC. Additionally, a phase 2 trial, PROFILE 1005, studies patients meeting similar criteria who have received more than one line of prior chemotherapy.

Crizotinib is also being tested in clinical trials of advanced disseminated anaplastic large-cell lymphoma, and neuroblastoma.

In February 2016 the J-ALEX phase III study comparing alectinib with crizotinib ALK-positive metastatic NSCLC was terminated early because an interim analysis showed that progression-free survival was longer with alectinib. These results were confirmed in a 2017 analysis.

As can be observed on Table 3, the racemization protocol performed with Shvo or vanadyl sulphate catalyst, lead to moderate conversions towards the desired chiral alcohol. It is important to note that under the reaction conditions studied, Shvo’s catalyst did not performed better then VOSO4, even presenting a decreasing on enantiomeric excess of the product, showing that VOSO4 could be an interesting and cheaper alternative for further improvements.19–25,32–34 Following our recent studies on the use of VOSO4 for DKR under continuous-flow conditions 31 we applied the reactions conditions already optimized for sec-phenylethanol to our substrate 1-(2,6-dichloro-3-fluorophenyl)ethanol. In this way, the reaction was performed in closed loop system due to the high reaction time needed for the kinetic resolution step. Although we did not observe any incompatibility between CAL B and VOSO4,19–25,32–34 as previously reported by other authors, a continuous flow packed-bed reactor was designed so that four layers of the immobilized enzyme and three layers of VOSO4 were alternately disposed along a glass column and physically separated by a thin cotton layer. The results obtained under different reaction times and flow rates are presented below (Table 4).

Continuous-flow DKR of 1-(2,6-dichloro-3-fluorophenyl)ethanol.

 

Entry    Flow Rate (mL.min?1)    Reaction Time (days)    Conv. (%)    e.e.prod (%)

1    1.0    1    28    98

2    3    38    98

3    5    44    98

4    0.5    1    32    98

5    3    47    96

6    5    57    96

7    0.1    1    33    88

8    3    47    84

9    5    47    82

Reaction conditions:1-(2,6-dichloro-3-fluoro-phenyl)-ethanol (2) (0,1 M), isopropenyl acetate (0,1 M) as acyl donor, in isooctane (15 mL) were carried out by pumping through the bed-packed reactor at different flow rates. The glass column was packed with immobilized N435 and VOSO4.XH2O alternately so that a 10 mL-packed-bed reactor with 4 layers of enzyme (each layer containing 500 mg of the catalyst) and 3 layers of VOSO4.XH2O (each layer containing 500 mg of the catalyst) separated by thin cotton layers. The bed-packed reactor was heated at 80 °C. Determined by GC-FID and enantioselectivity measured based on (S)-1-(2,6-dichloro-3-fluorophenyl)ethanol and the corresponding ester retention times.

The results presented on Table 4 show that under continuous-flow conditions the DKR mediated by Novozyme 435 and VOSO4, is more efficient in terms of conversion and reaction time when compared to the batch set-up, as observed in entry 6 (Table 4). No further improvement on reaction conversion could be observed increasing the reaction time, which seems to be a limitation in this specific case. Increasing the residence time by using low flow rates do not lead to better conversion and a small decrease on enantiomeric excess of the product could be observed (entries 7–9, Table 4). At 0.5 mL.min?1 a significant improve on reaction conversion could be obtained when compared to the batch process, it is important to note that despite the reaction has been performed for 5 days, the actual time of contact between reagents and catalysts is much less since it works on a closed loop system. Another advantage of DKR is the fact that the remaining starting material is racemic been able to be re-used in a different campaign without any further purification.

6.The Conclusion of Crizotinib

In conclusion we have developed different approaches towards production of chiral

1-(2,6-dichloro-3-fluorophenyl)ethanol (2), an important intermediate for Crizotinib (1) synthesis. Kinetic resolution was accomplished with very good conversions and high selectivity while dynamic kinetic resolution, also under batch conditions afforded poor results of conversions with good enenatiomeric excess of the product. Further improvement was obtained translating the dynamic kinetic resolution to a continuous-flow protocol where conversion could be improved with still good selectivity.

7.Where to  Buy Crizotinib powder?

AASraw is one of legit resource for Choosing, if more info. need to know, please  contact us.

Related Post: Crizotinib powder 877399-52-5 is an anti-cancer agent acting

Caffeic Acid Phenethyl Ester(CAS:104594-70-9)Supplement Online

Caffeic Acid Phenethyl Ester(CAS:104594-70-9)Supplement Online............................................1

1. Caffeic Acid Phenethyl Ester--CAS:104594-70-9............................................................................. 1

2. Caffeic Acid Phenethyl Ester: Technical Informations.....................................................................2

3. Caffeic Acid Phenethyl Ester: Physical Characteristics.................................................................... 3 (1) Activities of CAPE................................................................................................................... 3 (2) Antimicrobial Activity of CAPE............................................................................................... 3 (3) Cytotoxicity of CAPE...............................................................................................................4

4.  Attenuating  effects  of  caffeic  acid  phenethyl  ester  and  betaine  on  abamectin-induced hepatotoxicity and nephrotoxicity...................................................................................................... 5

5. Caffeic Acid Phenethyl Ester(CAS:104594-70-9)Synthesis........................................................ 6

(1)Results and Discussion-Caffeic Acid Phenethyl Ester....................................................... 8

(2)Conclusion--Caffeic Acid Phenethyl Ester....................................................................... 10

6. Caffeic Acid Phenethyl Ester Supplement..................................................................................... 11

 

1. Caffeic Acid Phenethyl Ester--CAS:104594-70-9

Caffeic acid phenethyl ester (CAPE) is     a     bioactive     compound     of propolis    extract.    The    literature search     elaborates     that     CAPE possesses                     antimicrobial, antioxidant,       anti-inflammatory, and    cytotoxic    properties.    The principal  objective  of  this  review article is to sum up and critically assess   the   existing   data   about therapeutic   effects   of   CAPE   in different  disorders.  The  findings elaborate that CAPE is a versatile therapeutically active polyphenol and an effective adjuvant of chemotherapy for enhancing therapeutic efficacy and diminishing chemotherapy-induced toxicities.

Caffeic acid phenethyl ester (CAPE) is a natural bioactive compound. It occurs in many plants. It is acquired from propolis obtained through extraction from honeybee    hives.     The    chemical    name    of    CAPE    is     2-phenylethyl (2E)-3-(3,4-dihydroxyphenyl)acrylate.   It   is   also   termed   as   phenylethyl caffeate or phenethyl caffeate. Its molecular formula is C17H16O4. The chemical structure of CAPE is given in Figure.For the first time, Grunberger et al. identified this hydrophobic polyphenol. This polyphenolic ester can also be synthesized by reacting caffeic acid with phenethyl alcohols. CAPE is a polyphenol with hydroxyl groups within the catechol ring which is responsible for its crucial role in many biological activities. The literature search showed an extensive research on the biological features of CAPE. The available studies narrate it as an effective moiety against various pathologies such as infections, oxidative stress, inflammation, cancer, diabetes, neurodegeneration, and anxiety. These therapeutic characteristics of CAPE have been summarized in this review article.

2. Caffeic Acid Phenethyl Ester: Technical Informations

 

Formal

Name

 

(E)-3-(3,4-dihydroxyphenyl)-2-propenoic acid, 2-phenylethyl ester

CAS Numbe r

 

 

104594-70-9

 

 

Synony ms

·     CAPE

·     2-Phenylethyl Caffeate

·     β-Phenylethyl Caffeate

Molecu lar Formul a

 

 

 

C17H16O4

Formul a Weight

 

 

284.3

Purity

≥98%

Formul ation

 

A crystalline solid

λmax

246, 300, 331 nm

SMILE S

 

O=C(OCCc1ccccc1)\C=C/c1ccc(O)c(O)c1

InChI Code

InChI=1S/C17H16O4/c18-15-8-6-14(12-16(15)19)7-9-17(20)21-11-10-

13-4-2-1-3-5-13/h1-9,12,18-19H,10-11H2/b9-7+

InChI Key

 

SWUARLUWKZWEBQ-VQHVLOKHSA-N

3. Caffeic Acid Phenethyl Ester: Physical Characteristics

(1) Activities of CAPE

Large number of studies has been conducted on various features of the biological  and  pharmacological  activities of CAPE  and  its  mode  of  action. Some of them are summarized below.

(2) Antimicrobial Activity of CAPE

There are many studies which demonstrate the antimicrobial activity of CAPE against Enterococcus faecalis, Listeria monocytogenes, Staphylococcus aureus [9–11], and Haemophilus influenzae showing that RNA, DNA, and cellular proteins are possible targets of CAPE [9, 12]. Thus, dietary intake of CAPE is useful for the treatment of sore throat, common cold, and wound. There is evidence that CAPE possesses promising fungicidal activity on fungi infecting tomato    without    causing    any    harm    to    the    fruit    [13].    Moreover, poly(lactic-co-glycolic acid) (PLGA) sutures containing CAPE have been proposed  to  have  antibacterial  activity  against  Staphylococcus  aureus  and

 

 

Escherichia  DH5α  bacteria;  this  activity  of  CAPE  was  attributed  to  the synthesis of reactive oxygen species (ROS) that destroy the outer membrane of bacteria [14]. In recent studies [15–17], CAPE has been proposed as a valuable inhibitor of HIV-1 integrase; therefore, this polyphenol is believed to be a potential anti-HIV therapy. Fesen et al. reported that the integration step is efficiently inhibited by CAPE than the initial cleavage step by HIV-1 integrase [18].  In  addition,  CAPE  and  its  esters,  in  a  concentration  range  of  1.0  to

109.6 mM, have also been tested in an HCV replicon cell line of genotype 1b

and found effective against replication of hepatitis C virus suggesting it a promising anti-HCV compound.

(3) Cytotoxicity of CAPE

An extensive literature is available regarding cytotoxicity studies of CAPE as documented in Tables 1 and 2. In the presence of CAPE, human pancreatic and colon cancer cells undergo apoptosis. The in vitro and in vivo studies reveal the growth inhibition of C6 glioma cells by CAPE.

There are many evidences which elaborate the antiproliferation activity of CAPE.  For  normal  cellular  proliferation,  adequate  levels  of  nuclear  factor (NF)-κB activity must be maintained. In some cancers, elevated activation of NF-κB is observed. To obstruct the NF-κB activation phenomenon, CAPE has been proved to be effective chemopreventive agent. Nutritional ingestion of CAPE  may  thus  be  valuable  for  patients  whose  tumors  express  steadily elevated levels of activated NF-κB, for instance, squamous head and neck carcinomas. It has been reported that CAPE render antitumor features devoid of causing cytotoxicity to normal cells. Su et al. proposed that cytotoxicity of CAPE is directly related to its apoptotic effect.

The antitumor activity of CAPE has been investigated to reveal its influence on cancer development including angiogenesis, tumor invasion, and metastasis. Liao et al. carried out a cytotoxicity study of CAPE in colon adenocarcinoma cells (CT26) and reported a dose-dependent decline in cell viability. Moreover, there was reduction in both expression of matrix metalloproteinase and production  of  vascular endothelial  growth  factor  from  CAPE-treated  CT26 cells resulting in the reduced angiogenesis and metastasis provide insight into the promising antimetastatic feature of CAPE. In addition, Song et al. reported that antiangiogenic property of CAPE was also accounted for    its    anti-inflammatory    effect    because    angiogenesis    and    chronic inflammation  depend  on  each  other.  An  anti-inflammatory  response  is obtained by blockage of angiogenesis. As far as mode of anticancer activity of CAPE is concerned, CAPE is capable of (i) inhibiting the xanthine oxidase which  can  metabolize  both  purine  and  pyrimidine  bases  and  obstruct  the nucleotide    production    pathway;    (ii)    suppressing    5-lipoxygenase;    (iii) inhibiting the tumor promoter-mediated oxidative responses in the culture of HeLa cells; (iv) inhibiting the azoxymethane-provoked colonic preneoplastic lesions and enzymatic processes related to colon carcinogenesis; (v) inducing apoptosis; and (vi) modulating the redox state of the cells. Attenuating effects of    caffeic    acid    phenethyl    ester    and    betaine    on    abamectin-induced hepatotoxicity and nephrotoxicity

4. Attenuating effects of caffeic acid phenethyl ester and betaine on abamectin-induced hepatotoxicity and nephrotoxicity

Abamectin (ABM) is a widely utilized potent anthelmintic and insecticidal agent. In this study, we investigated the protective effects of caffeic acid phenethyl  ester  (CAPE)  and  betaine  (BET)  against  ABM-induced hepatotoxicity and nephrotoxicity in rats. Forty rats were divided into five groups, receiving either oral saline solution (normal control), oral ABM at a dose of 2 mg/kg BW (1/5 LD50), CAPE (10 μmol/kg BW intraperitoneally) followed  by  ABM,  or  BET  supplementation  at  a  dose  of  250  mg/kg  BW followed by ABM administration, while group V rats received a combination of i.p. CAPE and oral BET in the same doses before receiving ABM. Biochemical analysis showed that ABM administration significantly (p < 0.05) increased serum levels of aminotransferases, alkaline phosphatase, lactate dehydrogenase, and cholesterol, as well as serum creatinine and urea. Compared  to  the  control  group,  ABM-intoxicated  rats  had  significantly  (p

< 0.05) higher tissue concentrations of nitric oxide and malondialdehyde, as

well as lower tissue glutathione concentration, total antioxidant capacity, and antioxidant enzymatic activity (glutathione peroxidase, superoxide dismutase, and catalase). Histopathological examination of hepatic and renal tissues of ABM-intoxicated rats showed acute inflammatory and necrotic changes. Pretreatment with CAPE and/or BET reversed the biochemical and histopathological  alterations  of  ABM  on  the  liver  and  kidneys.  Therefore, CAPE and BET  (alone  or  in  combination)  could  be  promising  protective agents   against   ABM-induced   hepatotoxicity   and   nephrotoxicity.   Future studies should confirm our findings and evaluate the other molecular effects are involved in the combination chemoprotection of CAPE and BET.

 

5.  Caffeic  Acid  Phenethyl  Ester ( CAS:104594-70-9 )

Synthesis

Due to the lethal side effects of synthetic chemical-based drugs, enthusiastic efforts are currently being applied to explore natural therapeutic agents with minimum toxicity. In this context, plant or herbal origin compounds are being studied to investigate the bioactivities of their natural active compounds. Polyphenols represent one of the most inten- sively studied groups of natural compounds.Caffeic acid has been proposed to act as a multipurpose active polyphenol and its derivatives have also been subjected to considerable study. One of the derivatives of caffeic acid is caffeic acid phenethyl ester (CAPE), which possesses prom- ising therapeutic potential against various pathologies such   as   inflammation,   cancer,   infection,   and   neurodegeneration.   This naturally bioactive, hydrophobic polyphenolic ester occurs in numerous plants and propolis and can also be prepared by reacting caffeic acid with phenethyl alcohols. The molecular formula of CAPE is C17H16O4 and is chemically recognized  as 2-phenylethyl (2E)-3-(3,4-  dihydroxyphenyl)acrylate (commonly termed as phenylethyl caffeate or phenethyl caffeate).

To achieve biological effects, CAPE should be adminis- tered at a therapeutic concentration so that prolonged maintenance of blood CAPE-concentration at a particular level could be achieved. Thus pharmacokinetic and bioavailability study of CAPE is crucial for determining its route of administration. Fig. 1 depicts the chemical struc- ture of CAPE consisting of a catechol ring and two hydroxyl groups; the former is considered to be responsible for its therapeutic features.  It  has  been  proposed  that  meta-  bolism  of  CAPE  is  a  saturable process because an increase in the area under the plasma concentrationetime curve for   CAPE was observed in a proportion higher than the increase in its dose. Moreover, volume of distribution and total body clearance values for CAPE were found to be in the ranges of 1555e5209 mL/kg and 42e172 mL/minute/kg, respectively, proposing that these values are in an inverse relationship   with  the   dose   of  CAPE.   Additionally,  no  relationship   was observed between the values of elimination half-life (21.24e26.71 minutes) of CAPE and its dose. Pharmacoki- netic study of CAPE showed its high values of volume of distribution and short elimination half-life, revealing its extensive distribution and swift elimination from the body after intravenous administration.  Another  pharmaco-  kinetic  study  of  CAPE  showed comparable results. Furthermore, pharmacokinetic analysis of CAPE and its metabolites should also be carried out after its oral administration. Another study has revealed that CAPE can efficiently cross the bloodebrain barrier in rats. Besides, although CAPE is stable for 6 hours in rat plasma, after which it hydrolyzes to caffeic acid, CAPE hydrolysis does not occur in human plasma showing its stability, possibly owing to the absence of carboxylesterase in this biofluid.

After an extensive search, no data were found about toxicity study of CAPE. Rather,  slight  toxicity  of  propolis  was  seen  in  a  range  of  2000e7300  g of propolis/kg in mice that is an origin of CAPE. At a dose of approximately 80 mM,  CAPE  generally  inhibits  the  activated  nuclear  factor-kB  (NF-kB)  and other transcription factors via suppressing their binding with DNA.

The objective in writing this review article was to sum- marize various published studies on the therapeutics of CAPE in inflammation and cancer, especially focusing on their molecular targets that are responsible for therapeutic effect of CAPE.

1Results and Discussion-Caffeic Acid Phenethyl Ester

There are many studies in the literature that elaborate the anti-inflammatory activity   of   CAPE.   Moreover,   CAPE-   induced   inhibition   of   normal   cell transformation to the neoplastic cell has also been reported. Table elaborates the dose (mM) or concentration causing 50% growth inhibition (mM) of CAPE effective in different cancer cell-lines. In addition, CAPE selectively destroys the cancerous cells leaving noncancer cells unaffected as observed in human immortal lung fibroblast WI-38 cells. These studies hypothesize that CAPE inhibits the release of arachidonic acid from the cell membrane, and moreover, suppresses  the  gene  responsible  for  cyclooxygenase-2  (COX-2)  expression. Moreover,  CAPE  suppresses  NF-kB  activity  by  limiting  the  formation  of NF-kB DNA and nuclear factor of activated T cells (NFAT)-DNA complexes and thus retarding NF-kB-dependent transcription in Jurkat cells. In 2005, Abdel-Latif  et  al  presented  anticancer  and  anti-inflammatory  activities  of CAPE  in  a  gastric  epithelial  cell  line,  claiming  that  CAPE  inhibits  the production  of  tissue  necrosis  factor-a  (TNF-a)  and  interleukin  (IL)-8;  it eventually retards the expression of NF-kB, AP-1, and COX-2. It is noteworthy to mention here that CAPE does not influence other tissues of body, and thus the usage of this natural anticancer agent is free of side effects with effective chemopreventive feature. This outcome elaborates the nutritional importance of CAPE, particularly for patients whose tumors express gradually elevated levels of above given activated transcription factors.

Lipopolysaccharide-mediated  inflammation  in  human  neutrophils  has  also been combated using CAPE which sup- presses the synthesis of TNF-a and IL-6. The same authors also found that CAPE attenuates the phosphorylation of extracellular signal-regulated kinase 1/2 and c-JunN-terminal kinase. Raso et al found that CAPE has potential for reducing inflammation through inhibiting IL-2 gene in acti- vated T-cells that are normally the source of inflammation.

Biological studies have also revealed the activity of CAPE against angiogenesis, tumor invasion, metastasis, prolifera- tion, and apoptosis in different cancers such  as  human  pancreatic  and  colon  cancer.  The  improve-  ment  in  the viability   of   colon   adenocarcinoma   cells   (CT26)   has   been   noted   in   a dose-dependent  manner  when  these  cells  are  treated  with  CAPE.  This cytotoxic  effect  of  CAPE  has  been  attributed  to  the  reduced  expression  of matrix metal- loproteinase and synthesis of vascular endothelial growth factor under the effect of CAPE. In this way, this chemical activity obstructs the angiogenesis and metastasis.

CAPE  can  suppress  apoptosis  via  inhibiting  the  activated  NF-kB,  Bak, Bcl-2-associated X protein (Bax), p53, extracellular signal-regulated ki- nase, c-Jun    and    p21ap,    c-JunN-terminal    kinase    and    Fas    ligand,    p38 mitogen-activated protein kinase (p38 MAPK), and caspase activity. Moreover, upregulation of Bel-2, the cellular inhibitor of apoptosis proteins 1 and 2, and X-linked inhibitor of apoptosis protein, release of cytochrome C, loss of mitochondrial transmembrane potential, and decrease in Mcl-1 by CAPE are also responsible for its antiapoptotic effect.

In many cancer cells, CAPE-mediated-cell cycle arrest has been reported through the suppression of various factors including cyclin B1. CAPE-induced necrosis has also been described . In addition, suppression of Akt.phosphorylation is also induced by CAPE, resulting in the in- hibition of cancer cell invasiveness.

The literature also contains many animal studies that reveal the inhibitory role of CAPE on tumor growth and metastasis. For example, at a dietary level of 0.15% CAPE, C57BL/6J-Min/þmice having a germ-line mutation exhibit 63% suppression in tumor growth through increased apoptosis and cell proliferation. At a dose of 50 mg/kg, CAPE-treated rats showed the emergence of colonerectal carcinoma pro- voked by azoxymethane. In addition, mice with C6 glioma xenografts have exhibited dose-dependent inhibition in tumor metastasis at 1e10 mg intraperitoneal dose of CAPE/kg/ day. As far as mechanisms of anticancer activity of CAPE are concerned, CAPE is capable of affecting various processes as summarized in Fig.

Through numerous experimental studies, the therapeutic potentials of CAPE against various cancers have been explored. The findings of those studies are summarized below and the possible target sites of CAPE action are also described.

2Conclusion--Caffeic Acid Phenethyl Ester

This literature mining study revealed anti-inflammatory and anticancer activities of CAPE. The possible molecular targets for the action of CAPE in inflammation and cancer include various transcription factors such as NF-kB. Based on the valuable data about the above presented bioactivities, clinical studies of CAPE should be conducted to explore its toxicities, if any.

6. Caffeic Acid Phenethyl Ester Supplement

Caffic Acid Phenethyl Ester is the best adjuvant for chemotherapy.At present, a lot of research has been devoted to  anti-cancer materials and inhibiting the spread of toxic substances. Caffic Acid Phenethyl Ester, which has been recognized by the market, has also been pushed to the forefront of the storm and attracted much attention.Therefore, a large number of suppliers began to invest in the r&d and production of caffic Acid Phenethyl Ester, which was put into the market.Among them, AASraw has attracted much attention. It has a professional  r&d  team  and  laboratory  cooperated  by  the  company,  which makes caffic Acid  Phenethyl Ester Supplement more reliable and authentic.

If you want to know more Caffeic Acid Phenethyl Ester Supplement, please

click here.....

Related Post: Caffeic Acid Phenethyl Ester(CAS:104594-70-9)Supplement Online

Aprepitant powder used for prevention of postoperative nausea and vomiting

1.What is Aprepitant?

Aprepitant (brand name: Emend) is an antiemetic chemical compound that belongs to a class of drugs called substance P antagonists (SPA). It mediates its effect by blocking the neurokinin 1 (NK1) receptor. It's used for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting. Aprepitant may also be useful in the treatment of cyclic vomiting syndrome and late-stage chemotherapy induced vomiting.

2.What is  Aprepitant powder?

Name:    Aprepitant powder

CAS:    170729-80-3

Molecular Formula:    C23H21F7N4O3

Molecular Weight:    534.4266624

Melt Point:    244-246°C

Storage Temp:    -20°C Freezer

Color:    White powder

Aprepitant is made up of a morpholine core with two substituents attached to adjacent ring carbons. These substitute groups are trifluoromethylated phenyl ethanol and fluorophenyl group. Aprepitant also has a third substituent (triazolinone), which is joined to the morpholine ring nitrogen. It has three chiral centres very close together, which combine to produce an amino acetal arrangement. Its empirical formula is C23H21F7N4O3.

Aprepitant is an off-white crystalline solid that has a molecular weight of around 534.53. It has a very limited solubility in water. It does have a reasonably high solubility in non-polar molecules such as oils. This would, therefore, suggest that aprepitant as a whole, despite having components that are polar, is a non-polar substance.

3.How does Aprepitant works?

Aprepitant is classified as an NK1 antagonist because it blocks signals given off by NK1 receptors. This, therefore, decreases the likelihood of vomiting in patients.

NK1 is a G protein-coupled receptor located in the central and peripheral nervous system. This receptor has a dominant ligand known as Substance P (SP). SP is a neuropeptide, composed of 11 amino acids, which sends impulses and messages from the brain. It is found in high concentrations in the vomiting center of the brain, and, when activated, it results in a vomiting reflex. In addition to this it also plays a key part in the transmission of pain impulses from the peripheral receptors to the central nervous system.

Aprepitant has been shown to inhibit both the acute and delayed emesis induced by cytotoxic chemotherapeutic drugs by blocking substance P landing on receptors in the brain's neurons. Positron emission tomography (PET) studies, have demonstrated that aprepitant can cross the blood brain barrier and bind to NK1 receptors in the human brain. It has also been shown to increase the activity of the 5-HT3 receptor antagonists ondansetron and the corticosteroid dexamethasone, which are also used to prevent nausea and vomiting caused by chemotherapy.

Aprepitant is taken orally in the form of a capsule. Before clinical testing, a new class of therapeutic agent has to be characterized in terms of preclinical metabolism and excretion studies. Average bioavailability is found to be around 60-65%. Aprepitant is metabolized primarily by CYP3A4 with minor metabolism by CYP1A2 and CYP2C19. Seven metabolites of aprepitant, which are only weakly active, have been identified in human plasma. As a moderate inhibitor of CYP3A4, aprepitant can increase plasma concentrations of co-administered medicinal products that are metabolized through CYP3A4. Specific interaction has been demonstrated with oxycodone, where aprepitant both increased the efficacy and worsened the side effects of oxycodone; however it is unclear whether this is due to CPY3A4 inhibition or through its NK-1 antagonist action. Following IV administration of a 14C-labeled prodrug of aprepitant (L-758298), which is converted rapidly and completely to aprepitant, approximately 57% of the total radioactivity is excreted in the urine and 45% in feces. No unchanged substance is excreted in urine.

One of the main features of aprepitant, and a major advantage it has over other chemotherapy-induced side-effect treatments, is its ability to selectively antagonize NK1 receptors, while having very low affinity to other common receptors such as serotonin, dopamine, and corticosteroid. It is estimated that aprepitant is at least 3,000 times more selective to NK1 receptors compared to these other enzyme transporter, The normal dosing of aprepitant given as 125 mg in the first day after chemotherapy and followed by

80 mg the following 2 days.

4.Where Aprepitant usage for?

Aprepitant is used to help prevent nausea and vomiting that can sometimes follow chemotherapy treatment. For patients receiving chemotherapy, nausea and vomiting may occur within the 24 hours immediately following treatment (acute), or several days later (delayed). Given in combination with other medications, aprepitant may prevent both acute and delayed nausea and vomiting. Aprepitant is not used to treat nausea and vomiting once they have already begun.

Aprepitant is used with other medications in adults and children 6 months of age and older to prevent nausea and vomiting that may occur within 24 hours after receiving cancer chemotherapy treatment. It is also used with other medications in adults and children 6 months of age and older to prevent delayed nausea and vomiting that may occur several days after receiving certain chemotherapy medications. Aprepitant is also used alone in adults to prevent nausea and vomiting caused by surgery. Aprepitant is not used to treat nausea and vomiting that you already have. Aprepitant is in a class of medications called antiemetics. It works by blocking the action of neurokinin, a natural substance in the brain that causes nausea and vomiting.

5.How should Aprepitant be used?

Aprepitant comes as a capsule and as an oral suspension (liquid) to take by mouth. To prevent nausea and vomiting caused by cancer chemotherapy, aprepitant is usually taken once daily, with or without food, during the first few days of your cancer chemotherapy treatment. You will probably take aprepitant 1 hour before your chemotherapy on days 1,

2, and 3 of your treatment. If you do not receive chemotherapy on days 2 and 3, then you will take aprepitant on those days in the morning. To prevent nausea and vomiting caused by surgery, aprepitant is usually taken as one dose within 3 hours before the start of surgery. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take aprepitant exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Aprepitant capsules come in two different strengths. Your doctor may prescribe both of the strengths for you to take at different times. You should be careful to take the right strength at the right time as directed by your doctor.

Swallow the capsules whole; do not split, chew, or crush them.

The oral suspension will be prepared by your healthcare provider and given to you in an oral dispenser. Store the oral dispenser in the refrigerator until it is time for your dose; however, it can be stored at room temperature for up to 3 hours before use. When ready to use, remove the cap from the dispenser before placing it in your mouth to slowly release the medication.

Aprepitant only works to prevent nausea and vomiting. Call your doctor if you already have these symptoms and do not begin to take aprepitant.

When used to prevent nausea and vomiting caused by cancer chemotherapy, aprepitant is usually used only during the first 3 days of the chemotherapy treatment cycles. Do not continue taking aprepitant longer than instructed by your doctor.

6.Aprepitant Dosage

Usual Adult Dose for Nausea/Vomiting - Chemotherapy Induced

MODERATELY TO HIGHLY EMETOGENIC CANCER CHEMOTHERAPY (HEC/MEC): Oral Capsules:

-Day 1: 125 mg orally once 1 hour before chemotherapy

-Days 2 and 3: 80 mg orally once a day, 1 hour before chemotherapy OR in the morning (if chemotherapy is not given on Days 2 and 3)

-Duration of therapy: 3 days/cycle

Oral Suspension:

-Day 1: 3 mg/kg orally once 1 hour before chemotherapy

---Maximum dose: 125 mg/dose

-Days 2 to 3: 2 mg/kg orally once a day, 1 hour before chemotherapy OR in the morning (if chemotherapy is not given on Days 2 and 3)

---Maximum dose: 80 mg/dose

-Duration of therapy: 3 days/cycle

Comments:

-The recommended dosage of dexamethasone is 12 mg orally on Day 1 administered 30 minutes prior to chemotherapy and 8 mg orally in the mornings on Days 2 through 4 (HEC) or Days 2 through 3 (MEC).

-The 5-HT3 antagonist is administered on Day 1 only. Consult the package insert for the

5-HT3 antagonist dosing prior to initiation of treatment.

-This drug may be taken with or without food.

Uses:

-In combination with other antiemetic agents for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of HEC including

high-dose cisplatin

-In combination with other antiemetic agents for the prevention of nausea and vomiting associated with initial and repeat courses of MEC

Usual Adult Dose for Nausea/Vomiting - Postoperative

40 mg orally once within 3 hours prior to induction of anesthesia

Use: Prevention of nausea and vomiting Usual Pediatric Dose for Nausea/Vomiting - Chemotherapy Induced

12 years and older: MEC/HEC:

Oral Capsules:

-Day 1: 125 mg orally once 1 hour before chemotherapy

-Days 2 and 3: 80 mg orally once a day, 1 hour before chemotherapy OR in the morning (if chemotherapy is not given on Days 2 and 3)

-Duration of therapy: 3 days/cycle

Oral Suspension:

-Day 1: 3 mg/kg orally once 1 hour before chemotherapy

---Maximum dose: 125 mg/dose

-Days 2 to 3: 2 mg/kg orally once a day, 1 hour before chemotherapy OR in the morning (if chemotherapy is not given on Days 2 and 3)

---Maximum dose: 80 mg/dose

-Duration of therapy: 3 days/cycle

Comments:

-If a corticosteroid (e.g., dexamethasone) is coadministered, patients should be given

50% of the recommended pediatric dose on Days 1 to 4. Consult the package insert for the corticosteroid dosing prior to initiation of treatment.

-The 5-HT3 antagonist is administered on Day 1 only. Consult the package insert for the

5-HT3 antagonist dosing prior to initiation of treatment.

-This drug may be taken with or without food.

Uses:

-In combination with other antiemetic agents for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of HEC including

high-dose cisplatin

-In combination with other antiemetic agents for the prevention of nausea and vomiting associated with initial and repeat courses of MEC

7.Other Comments for Aprepitant

Administration advice:

-Take with or without food.

-Oral suspension: Oral syringes should be placed along the inner cheek, and should be dispensed slowly.

-Oral capsules: Swallow whole.

-For prevention of CINV, take first dose 1 hour prior to chemotherapy.

-For prevention of PONV, receive medication within 3 hours prior to induction of anesthesia.

Storage requirements:

-Oral suspension: Refrigerate; use within 72 hours of preparation, and discard any remaining suspension after 72 hours.

General:

-Limitations of use: Use has not been studied for the treatment of established nausea and vomiting.

-Patient profiles may change during chronic continuous administration; chronic use is not recommended.

Monitoring:

-Hematologic: INR in patients on chronic warfarin therapy

-Hypersensitivity: Hypersensitivity reactions at any time during treatment

Patient advice:

-Patients should be advised to report all concurrent prescription and nonprescription medications or herbal products they are taking.

-Instruct patients to immediately report any signs/symptoms of Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity reactions.

-Patients should be advised to speak to healthcare provider if pregnant, intend to become pregnant, or are breastfeeding; patients using hormonal contraception to prevent pregnancy will need to speak with their health care provider about using a non-hormonal back-up method of birth control for up to 2 months after completing therapy.

8.What special precautions should I follow?

Before taking aprepitant

·  tell  your  doctor  and  pharmacist  if  you  are  allergic  to  aprepitant,  any  other medications, or any of the ingredients in aprepitant capsules or oral suspension. Ask your pharmacist for a list of the ingredients.

·  do not take aprepitant if you are taking pimozide (Orap). Your doctor will probably tell you not to take aprepitant if you are taking this medication.

·  tell  your  doctor  and  pharmacist  what  other  prescription  and  nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: anticoagulants ('blood thinners')   such   as   warfarin   (Coumadin,   Jantoven);   antifungals   such   as itraconazole (Onmel, Sporanox) and ketoconazole ; benzodiazepines such as alprazolam (Xanax), diazepam (Valium), midazolam , and triazolam (Halcion); cancer chemotherapy medications such as ifosfamide (Ifex), irinotecan (Camptosar), vinblastine, and vincristine (Marqibo Kit); carbamazepine (Equetro, Tegretol, Teril); clarithromycin (Biaxin, in Prevpac); diltiazem (Cardizem, Cartia, Tiazac); HIV protease inhibitors such as nelfinavir (Viracept) and ritonavir (Norvir); hormonal contraceptives (birth control pills, patches, rings, and injections); nefazodone; oral steroids such as dexamethasone and methylprednisolone (Medrol);   phenytoin   (Dilantin,   Phenytek);   rifampin   (Rifadin,   Rimactane,   in Rifamate, in Rifater); and troleandomycin (TAO; no longer available in U.S.). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with aprepitant, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.

·     tell your doctor if you have or have ever had liver disease.

·     tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.

If you are taking birth control medications during treatment with aprepitant you should also use an additional method of birth control to avoid pregnancy during treatment with aprepitant and for one month after your final dose. Talk to your doctor about birth control methods while  you  are  taking aprepitant and after treatment. If you become pregnant while taking aprepitant, call your doctor.

9.Aprepitant other uses

Major depression

Encouraged by positive results in their early controlled studies of aprepitant (300 mg/d with enforced food intake) and L-759,274(another NK1 receptor antagonist), as well as those of CP-122,721 (Pfizer) in patients with major depressive disorder, Merck & Co. conducted Phase III clinical trials on aprepitant in which patients received 80 mg or 160 mg/d (a new formulation, prescribed without enforced food intake) as a treatment for major depressive disorder. Despite achieving 90-95% receptor occupancy of aprepitant in certain brain regions, negative clinical results were observed in three actively controlled studies. The company has since abandoned plans to market aprepitant 160 mg as an antidepressant. Subsequently, large clinically positive double blind controlled studies with two additional NK1 receptor antagonists, casopitant, and orvepitant (both GlaxoSmithKine compounds) have been published in peer reviewed medical journals. This work now replicates the early findings of Merck and Co with aprepitant and L-759,274, and of Pfizer with CP-122,721. Arguably, the weight of preclinical data and positive clinical evidence provides evidence that NK1 receptor antagonism, including that of aprepitant, is a distinct antidepressant mechanism. Across all these studies, efficacy appeared to be dose-related. Only mild, transient, and tolerable side effects, not those typically observed with either the SSRI, SNRI, or NRI classes of antidepressants, have been observed.

Beyond suggestions that PET receptor occupancy must not be used routinely to cap dosing for new medical indications for this class, or that > 99% human receptor occupancy might be required for consistent psycho-pharmacological or other therapeutic effects, critical scientific dissection and debate of the above data might be needed to enable aprepitant, and the class of NK1 antagonists as a whole, to fulfill preclinically predicted utilities beyond CINV (i.e., for other psychiatric disorders, addictions, neuropathic pain, migraine, osteoarthritis, overactive bladder, inflammatory bowel disease, and other disorders with suspected inflammatory or immunological components (see anti-cancer below.) However, most data remain proprietary and thus reviews on the expanded clinical potential for drugs like aprepitant range from optimistic to crepe-hanging. 

Related Post: Aprepitant powder used for prevention of postoperative nausea and vomiting

What Is an ICO and How Does It Work?

ICO has proven to be a revolutionised way for many companies and projects to raise money. ICO can be said as the blend of conventional methods and advanced techniques. The primary thing to consider here is that investors investing in the ICO will be 100% free of risk due to the technology used.

Till now, most of the ICO funds have been collected via Bitcoins (BTC) or Ether (ETH). While performing the ico review, the project produces a Bitcoin or Ethereum address to receive funds and then, shows it on the respective web page. The procedure is same as opening a bank account, and then showcasing it on a particular web page to people so that they may send money.

Initial coin offering (ICO) is basically an illegal way to collect crowdfunding via various cryptocurrencies (fiat currencies in a few cases) and is functioned by cryptocurrency organisations to obtain the capital funds required to execute the project. In an ICO, a particular part of the recently issued cryptocurrency is being sold to investors in exchange for any legalised tender or any other cryptocurrency. It can be said as token sale or crowd sale that involves taking investment amount from investors and providing them with some features associated with the project to be launched.

IPO, i.e. Initial Public offering is a process somehow relatable to ICO in which investors receive shares in the ownership of the company. While in ICO, the investors purchase coins of the company that can increase in value if the business gets amplified.

The first token sale, i.e. an ICO was conducted by Mastercoin in July 2013. Ethereum collected money through an ICO in 2014. ICO has taken an entirely new definition in past years. In May 2017, there were approx. 20 offerings, and also a recent web browser Brave's ICO generated about $35 million in just 30 seconds. Till the end of August 2017, a total of 89 ICO coin sales worth $1.1 billion had been conducted starting from January 2017.

Investors send Bitcoin, Ethereum or any other cryptocurrency to the given address and then in exchange, they get new tokens that can benefit them greatly if the project gets hit.

Related Post: Reviews of ICO (Initial Coin Offerings)

The Benefits of Wearing Women's Sneakers

Sneakers with rubber soles minimize impact and shock from running, walking, and other vigorous activities like climbing and dancing. These give stability and control to prevent the foot, ankle, and heel suffer from pain and injury. Some sneakers even have insoles made especially for flat-footed women to support their feet while walking and running. A number of athletic sneakers cater the needs of women who call for specific types of foot support for different activities.

Because of their soft rubber soles that cushion and protect the feet, sneakers are comfortable to wear even after a long time. Most athletic sneakers have used mesh materials that allow the feet to breath through the process of ventilation. These mesh materials have tiny holes that help reduce heat and formation of wetness that often leads to foot odor and allergies. Sneakers used for dancing activities have flexible materials that allow ease of movement and emphasis of foot work steps. Thick, cloth materials are also used because of their soft properties ideal for women who are looking for sneakers that are soft and comfortable to the feet.

Just like any other footwear, sneakers come in various forms used for different purposes. Some women prefer to put on these because sneakers allow foot and leg muscle relaxation without the need to sacrifice their style when it comes to being in fashion.

Companies and manufacturers of sneakers know that most women are after practicality and value for money that was why they started to create lines of Steel toe sneakers womens that come in styles and designs that are suitable to wear during different activities. A pair of sneakers can take a woman from her walking activity to a casual day in a mall together with her family or friends. High-cut, sneaker-boot types used during winter help promote heat and warmth. During summer, the same pair of footwear, when worn together with shorts and miniskirts, creates a sexier and more stylistic appeal.

Aside from the usual types which used combinations of rubber, leather, and cloth materials, sneakers that are available in the market today come in styles and designs that are up-to-date with the latest trends in fashion.

Sneakers made of cloth have trimmings and embellishments like glitters and rhinestone for a more feminine appeal. Some even have canvas paintings and drawings that show self-expression of women through the form of art.

Sneakers of slip-on types have also become a trend for those who want to get a more feminine look by ditching shoelaces and choosing those that have Velcro and straps instead.

Related Post: The Essential Guide to Steel Toe Boots For Road Construction Workers

How to Paint a Sunset

Shake each paint well. You need to do this to make sure the chemicals are mixed.

Put a dab of each colored paint on the paper plate far enough away that they will not run together, how to paint a beautiful sunset.

Use yellow paint to create a straight horizontal line either just above or just below the middle of the canvas. This is your horizon line.

Make a circle sun in the middle of the canvas just above the horizon line.

Pull yellow outwards from the edges of the sun toward the edge of the canvas.Stay going left to right with your brushstrokes.

Clean your brush in between the color changes in the water cup and dab it dry on the paper towel.

Add orange above the yellow.

Blend the orange into the yellow by pulling it slightly down into the yellow. Pull the yellow into the orange to give an even blend. Notice the left side of the image is blended in while the right side is not.

Add red the same way you added the orange. Make sure to blend it like you did the orange and yellow.

In the left and right top corners of the canvas add some purple. Pull some of it down the sides of the canvas and into the middle of the top of the canvas, but be sure not to pull it too far that it no longer can blend.

Around the sun add some white highlights to make it stand out. Pull the white into the surrounding colors. If it starts to fade into the colors too much you can always add more.

Go back over the sun in yellow one more time to be sure that it is vibrant.

You can finish the bottom of the sunset however you would like! This one was finished with water. It was made with the simple brush strokes and blending just like the sunset was made. You could also finish it with black to make a silhouette painting. Or you could make the sunset the whole painting. Just some suggestions!

Related Post: How to Paint Realistic Sunrises With Acrylics

View older posts »